Kiniksa Pharmaceuticals International, plc
KNSA
株式のランク
#2871
Kiniksa Pharmaceuticals International, plc, a biopharmaceutical company,... Kiniksa Pharmaceuticals International, plc, a biopharmaceutical company, develops and commercializes medical therapies in the United States, the United Kingdom, and internationally. The company offers ARCALYST, an interleukin-1alpha and 1beta cytokine trap for the treatment of recurrent pericarditis, a chronic autoinflammatory cardiovascular disease and cardiac sarcoidosis. It also develops KPL-387, an investigational and fully human immunoglobulin G2 monoclonal antibody, which is Phase 2/3 clinical trial for the treatment of recurrent pericarditis; and KPL-116, a Fc-modified immunoglobulin G2 monoclonal antibody, which is in pre-clinical stage. The company was formerly known as Kiniksa Pharmaceuticals, Ltd. and changed its name to Kiniksa Pharmaceuticals International, plc in June 2024. Kiniksa Pharmaceuticals International, plc was incorporated in 2015 and is based in London, the United Kingdom.
株価
$83.13
時価総額
$6.49B
変化（1日）
4.59%
変化（1年）
113.21%
国
GB
取引 Kiniksa Pharmaceuticals International, plc (KNSA)
カテゴリー
Healthcare
Kiniksa Pharmaceuticals International, plc（KNSA）の発行済株式数
June 2026 時点の発行済株式数 77.58M
Kiniksa Pharmaceuticals International, plc の最新の財務報告および株価によると、現在の発行済株式数は 77.58M です。December 2023 の終わりには、同社は 70.06M 株の発行済株式 を有していました。発行済株式数は、通常、株式分割や自社株買いによって影響を受けます。
Kiniksa Pharmaceuticals International, plc（KNSA）の発行済株式数の履歴（2016 ～ 2026）
各年末時点の発行済株式数
| 年 | 発行済株式数 | 変化 |
|---|---|---|
| 2026 (TTM) | 77.58M | 8.62% |
| 2024 | 71.42M | 1.95% |
| 2023 | 70.06M | 0.98% |
| 2022 | 69.38M | 1.17% |
| 2021 | 68.58M | 10.89% |
| 2020 | 61.84M | 14.42% |
| 2019 | 54.05M | 82.92% |
| 2018 | 29.55M | -8.99% |
| 2017 | 32.47M | 0.00% |
| 2016 | 32.47M | 0.00% |
類似企業や競合他社の発行済株式数
| 企業 | 発行済株式数 | 差 | 国 |
|---|---|---|---|
| 445.06M | 473.70% |
US
|
|
| - | - |
SE
|
|
| - | - |
FR
|
|
| - | - |
IT
|
|
| 105.38M | 35.83% |
US
|
